ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS

TETRAHYDROISOQUINOLINE COMPOUNDS OF FORMULA I ( FORMULA 1 )AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN WHICH :- R1 REPRESENTS ONE OR MORE SUBSTITUENTS SELECTED FROM M, HALO, HYDROXY, ALKYL ( OPTIONALLY SUBSTITUTED BY HYDROXY, ALKOXY, ALKYLTHIO, ALKYLSULPHINYL, ALKYL- SULPHONYL, NITRO, CYANO, POLYHALOALKYL, POLYHALOALKOXY, PHENYL (OPTIONALLY SUBSTITUTED BY ONE OR MORE OF HALO, ALKYL OR ALKOXY), OR R1 IS OPTIONALLY ALKYLATED CARBAMOYL;R2 REPRESENTS A SATURATED OR UNSATURATED ALIPHATIC GROUP OPTIONALLY SUBSTITUTED BY HYDROXY OR ALKOXY;E REPRESENTS AN ALKYLENE CHAIN OPTIONALLY SUBSTITUTED BY ONE OR MORE ALKYL GROUPS;AND G REPRESENTS (A) OPTIONALLY SUBSTITUTED SATURATED OR UNSATURATED ALICYCLIC GROUP CONTAINING 3 TO 8 CARBON ATOMS, OR (B) OPTIONALLY SUBSTITUTED SATURATED OR UNSATURATED ALIPHATIC CHAIN CONTAINING 1 TO 12 CARBON ATOMS, OR (C) OPTIONALLY SUBSTITUTED 5 OR 6 MEMBER HETEROCYCLIC RING CONTAINING OR MORE N OR O ATOMS OR SON GROUPS IN WHICH N IS 0, 1 OR 2;AND O-ACYLATED DERIVATIVES THEREOF WHICH PROVIDE LIPOPHILIC ESTERS UTILITY IN ANALGESIA OR IN THE TREATMENT OF PAYCHOSES (E.G. SCHIZOPHRENIA), PARKINSON'''S DISEASE, LESCH-NYAN SYNDROME, ATTENTION DEFICIT DISORDER OR COGNITIVE IMPAIRMENT OR IN THE RELIEF OF DRUG DEPENDENCE OR TARDIVE DYSKINESIA.